Evidence map›Paper›PMID 20140090›Full record

ArticlePloS one2010

Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study.

Charles X Kim, Kent R Bailey, George G Klee, Allison A Ellington, Guanghui Liu, Thomas H Mosley, Hamid Rehman, Iftikhar J Kullo

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03427489 (A Biorepository for Discovering Novel Biochemical and Genetic Markers of Coronary Heart Disease in Qatar), which is not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03427489 completednot on this mapstarted 2013, after this paper: background citation

A Biorepository for Discovering Novel Biochemical and Genetic Markers of Coronary Heart Disease in Qatar (QCBio)

TypeobservationalSponsorHamad Medical CorporationRan2013 to 2018Enrolled2,100ConditionsCoronary Heart Disease (CHD)
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 88 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Sex differences in proteomics of cardiovascular disease -International journal of cardiology. Heart & vasculature · 2025
    Article
  6. Article
  7. Metabolomic heterogeneity of ageing with ethnic diversity: a step closer to healthy ageing.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Midlife Systemic Inflammation Is Associated With Frailty in Later Life: The ARIC Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Charles X KimMayo Clinic, Rochester, Minnesota, United States of America.
Kent R Bailey
George G Klee
Allison A Ellington
Guanghui Liu
Thomas H Mosley
Hamid Rehman
Iftikhar J Kullo
WinnMed · USMayo Clinic · US

Funding

ZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4M
Proteomic Markers of ArteriosclerosisU01HL081331 · NHLBI · MAYO CLINIC ROCHESTER · PI KULLO, IFTIKHAR J · 2005 to 2008
$3.7M
NCRR NIH HHS M01 RR000585NCRR NIH HHS M01 RR00585NHLBI NIH HHS HL-81331NHLBI NIH HHS U01 HL081331
6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) susceptibility differs between men and women and varies with ethnicity. This variability is not entirely explained by conventional CVD risk factors. We examined differences in circulating levels of 47 novel protein markers of CVD in 2561 men and women of African-American (AA) and non-Hispanic White (NHW) ethnicity, enrolled at geographically distinct sites. METHODOLOGY/PRINCIPAL

findingsParticipants (1,324 AAs, mean age 63.5 y, 71% women; 1,237 NHWs, mean age 58.9 y, 57% women) belonged to sibships ascertained on the basis of hypertension. Solid-phase immunoassays and immunoturbidometric, clot-based, chromogenic, and electrophoretic assays were used to measure the 47 protein markers in plasma or serum. Marker levels were log transformed and outliers were adjusted to within 4 SD. To identify markers independently associated with sex or ethnicity, we employed multivariable regression analyses that adjusted for conventional risk factors, prior history of CVD, medication use and lifestyle factors (physical activity, alcohol consumption and education). Generalized estimating equations were used to correct for intrafamilial correlations. After adjustment for the above covariates, female sex was associated with higher levels of 29 markers and lower levels of 6 markers. Female sex was independently associated with higher levels of several inflammatory markers as well as lipoproteins, adipokines, natriuretic peptides, vasoconstrictor peptides and markers of calcification and thrombosis. AA ethnicity was associated with higher levels of 19 markers and lower levels of 6 markers, including higher levels of several inflammatory makers, higher leptin and lower adiponectin levels, lower levels of vasodilator-natriuretic peptides, higher levels of vasoconstrictor-antidiuretic peptides and markers of calcification and thrombosis. CONCLUSIONS/SIGNIFICANCE: Plasma levels of several novel protein markers of CVD differ significantly in the context of sex and ethnicity. These results have implications for individualized CVD risk assessment.

Indexed as

AgedArteriosclerosisBiomarkersBlack or African AmericanCardiovascular DiseasesFemaleHumansImmunoassayMaleMiddle AgedMultivariate AnalysisProteomeProteomicsRegression AnalysisRisk FactorsSensitivity and SpecificityBiomarkersProteome

Identifiers

PMID20140090
PMCPMC2816715
OpenAlexW2030735640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.